227199-07-7

Basic information

• Product Name: N-BENZO[1,3]DIOXOL-5-YL-2-CHLORO-ACETAMIDE
• Synonyms: BUTTPARK 80\07-96;AKOS BBS-00003878;TIMTEC-BB SBB001861;N-(1,3-BENZODIOXOL-5-YL)-2-CHLOROACETAMIDE;N-(2-CHLOROACETYL)-3,4-METHYLENEDIOXYANILINE;N-BENZO[1,3]DIOXOL-5-YL-2-CHLORO-ACETAMIDE;N-BENZO[3,4-D]-1,3-DIOXOLAN-5-YL-2-CHLOROACETAMIDE;N-BENZO[3,4-D]1,3-DIOXOLAN-5-YL-2-CHLOROETHANAMIDE
• CAS NO: 227199-07-7
• Molecular Formula: C₉H₈ClNO₃
• Molecular Weight: 213.62
• Mol File: 227199-07-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 155-156
• Boiling Point: 399.5 °C at 760 mmHg
• Flash Point: 195.4 °C
• Appearance: /
• Density: 1.472 g/cm³
• Vapor Pressure: 1.36E-06mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.84±0.20(Predicted)
• CAS DataBase Reference: N-BENZO[1,3]DIOXOL-5-YL-2-CHLORO-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZO[1,3]DIOXOL-5-YL-2-CHLORO-ACETAMIDE(227199-07-7)
• EPA Substance Registry System: N-BENZO[1,3]DIOXOL-5-YL-2-CHLORO-ACETAMIDE(227199-07-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 227199-07-7(Hazardous Substances Data)

Usage

General Description

N-Benzo[1,3]dioxol-5-yl-2-chloro-acetamide is a chemical compound with a molecular structure consisting of a benzene ring fused with a dioxolane ring and a chloroacetamide group. N-Benzo[1,3]dioxol-5-yl-2-chloro-acetamide is used in the synthesis of various pharmaceuticals and agrochemicals. It is also known for its antiviral and antimicrobial properties, making it a potential candidate for the development of new drugs. Additionally, it is used as a reagent in organic synthesis, particularly in the preparation of heterocyclic compounds. This chemical has garnered interest within the scientific community due to its diverse applications and potential therapeutic benefits.

InChI:InChI=1/C9H8ClNO3/c10-4-9(12)11-6-1-2-7-8(3-6)14-5-13-7/h1-3H,4-5H2,(H,11,12)

Upstream product

• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 936633-12-4 2-(4-aminophenoxy)-N-benzo[1,3]dioxol-5-ylacetamide 
• 939246-33-0 N-1,3-benzodioxol-5-yl-2-(biphenyl-4-yloxy)acetamide 
• 326610-45-1 N-1,3-benzodioxol-5-yl-2-(3-phenoxyphenoxy)acetamide 
• 850478-03-4 N-1,3-benzodioxol-5-yl-2-[4-(trifluoromethyl)phenoxy]acetamide 
• 701260-75-5 N-benzo[1,3]dioxol-5-yl-2-(4-nitrophenoxy)acetamide 

Relevant articles and documents

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1-42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.

Structure-based design, synthesis, and biological evaluation of isatin derivatives as potential glycosyltransferase inhibitors

Peptidoglycan glycosyltransferase (PGT) has been shown to be an important pharmacological target for the inhibition of bacterial cell wall biosynthesis. Structure-based virtual screening of about 3 000 000 commercially available compounds against the crystal structure of the glycosyltransferase (GT) domain of the Staphylococcus aureus penicillin-binding protein 2 (S. aureus PBP2) resulted in identification of an isatin derivative, 2-(3-(2-carbamimidoylhydrazono)-2-oxoindolin-1-yl)-N-(m-tolyl)acetamide (4) as a novel potential GT inhibitor. A series of 4 derivatives were synthesized. Several compounds showed more active antimicrobial activity than the initial hit compound 4, in particular 2-(3-(2-carbamimidoylhydrazono)-2-oxoindolin-1-yl)-N-(3-nitrophenyl)acetamide (4l), against Gram-positive Bacillus subtilis and S. aureus with MIC values of 24 and 48 lg/mL, respectively. Saturation transfer difference (STD) NMR study revealed that there is a binding contact between 4l and the GT domain of S. aureus PBP2. Competitive STD-NMR further proved that 4l and moenomycin A bind to GT domain in a competitive manner. Molecular docking study suggests a potential binding pocket of 4l in the GT domain of S. aureus PBP2. Taken together, compound 4l would provide a new scaffold for further development of potent GT inhibitors.